The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2025 | The impact of early blast clearance on post-transplant outcomes in patients with AML
Julian Ronnacker, MD, University of Münster, Münster, Germany, discusses the impact of early blast clearance during sequential conditioning on post-transplant outcomes in patients with acute myeloid leukemia (AML). The study found that early blast clearance did not affect the risk of relapse or overall survival outcomes after transplantation, aligning with previous findings from large randomized trials. This interview took place at the 19th International Symposium on Acute Leukemias (ISAL XIX) in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We investigated in how far early blast clearance during sequential conditioning using high-dose melphalan affects post-transplant outcome. And we discovered that early blast clearance, counter-intuitively, did not affect the risk of relapse after transplantation and did not significantly alter overall survival outcomes. This further underscores results from big randomized trials like the ASAP trial where the reduction of AML disease burden in relapsed or refractory AML patients did not alter AML disease cause and survival...
We investigated in how far early blast clearance during sequential conditioning using high-dose melphalan affects post-transplant outcome. And we discovered that early blast clearance, counter-intuitively, did not affect the risk of relapse after transplantation and did not significantly alter overall survival outcomes. This further underscores results from big randomized trials like the ASAP trial where the reduction of AML disease burden in relapsed or refractory AML patients did not alter AML disease cause and survival. So our study nicely aligns with other findings from large prospective trials and further elucidates the importance in order to find novel strategies to deal with patients with high leukemic burden and besides our primary findings in terms of early plus clearance we discovered quite nice survival outcomes for these patients despite the high risk conveyed by high leukemic burden.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
